Innovative Medicines Initiative

From Powerbase
Revision as of 13:36, 9 May 2009 by Marisa de Andrade (talk | contribs) (New page: {{Template:Pharma_Portal_badge}} ==History== The Innovative Medicines Initiative (IMI) is a partnership between the European Community and the [[European Federation of Pharmaceut...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

History

The Innovative Medicines Initiative (IMI) is a partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA). According to its website: 'The objective of IMI is to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector.'[1]

Achieving the Objectives

  • The European Commission and EFPIA propose to create and operate a new Public Private Partnership, the IMI Joint Undertaking, which will fund Patient Centred Projects.
  • These Patient Centred Projects will consider delays in the process of getting new drugs on the market and address these issues in order to speed up the process.
  • Patient Centred Projects will be conducted with European patient organisations, universities, hospitals, regulatory authorities, and small and large companies.[2]
  • Representatives from the pharmaceutical industry, patient groups, universities, regulatory authorities and hospitals will collaborate to form the IMI Strategic Research Agenda which will: predict the safety and efficacy of drugs; and bridge gaps in knowledge management, education and training.[3]

People

From the industry side:[4]

From the European Commission:

Funding

  • Pharmaceutical companies fund their own participation - 100%.
  • Pharmaceutical companies provide R&D resources such as staff, laboratory facilities, materials and clinical research.
  • Through the EFPIA, companies will fund half of the cost of the IMI Executive Office - about 4% of the total budget.
  • Public money will go exclusively to other participants (public sector, SMEs, patient groups, academics.[5]

Contact

Address:
IMI
c/o EFPIA
Leopold Plaza Building
Troonstraat
Rue du Trône 108
B-1050
Brussels
Belgium
Website:
http://www.efpia.org

Notes

  1. IMI. IMI Objectives Accessed on 9 May 2009
  2. IMI. IMI Objectives Accessed on 9 May 2009
  3. IMI. IMI Objectives Accessed on 9 May 2009
  4. IMI. IMI Governance Accessed on 9 May 2009
  5. IMI.IMI Funding. Accessed on 9 May 2009.